Haemonetics Analyst Ratings
Haemonetics Positioned for Strong Growth: Buy Rating Justified Amidst Operational and Financial Optimism
Haemonetics Analyst Ratings
Haemonetics Analyst Ratings
Haemonetics (HAE) Gets a Hold From Needham
Haemonetics Analyst Ratings
Barrington Research Maintains Outperform on Haemonetics, Maintains $105 Price Target
Needham Remains a Hold on Haemonetics (HAE)
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE), Biogen (BIIB) and Axsome Therapeutics (AXSM)
Haemonetics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Shattuck Labs (STTK)
Analysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), ALX Oncology Holdings (ALXO)
Needham Sticks to Its Hold Rating for Haemonetics (HAE)
Haemonetics (HAE): Promising Growth in Plasma Segment and International Expansion Fuels Buy Rating Despite Short-Term Concerns
Haemonetics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Haemonetics (HAE) and CVRx (CVRX)
Barrington Cuts Price Target on Haemonetics to $105 From $114 on 'Macro Concerns', Keeps Outperform Rating
Buy Rating for Haemonetics: Consistent Performance, Financial Outperformance and Promising New Products
Analysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), Optinose (OPTN)
Strategic Acquisition of OpSens Boosts Haemonetics' Growth Prospects: A Buy Rating Analysis